Kyorin Pharmaceutical Co (TSE:4569) Cash-to-Debt : 0.92 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Kyorin Pharmaceutical Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.92.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Kyorin Pharmaceutical Co couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Kyorin Pharmaceutical Co's Cash-to-Debt or its related term are showing as below:

TSE:4569' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.89 Med: 1.82 Max: 41.85
Current: 0.92

During the past 13 years, Kyorin Pharmaceutical Co's highest Cash to Debt Ratio was 41.85. The lowest was 0.89. And the median was 1.82.

TSE:4569's Cash-to-Debt is ranked worse than
50.66% of 989 companies
in the Drug Manufacturers industry
Industry Median: 0.96 vs TSE:4569: 0.92

Kyorin Pharmaceutical Co Cash-to-Debt Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kyorin Pharmaceutical Co Cash-to-Debt Chart

Kyorin Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

1.35

1.40

1.41

1.27

0.91

Kyorin Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.89	0.91	0.89	1.26	0.92

Competitive Comparison of Kyorin Pharmaceutical Co's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyorin Pharmaceutical Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Cash-to-Debt falls into.

Kyorin Pharmaceutical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Kyorin Pharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	19394	/	(10434	+	10843)
	=	0.91

Kyorin Pharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	19149	/	(20300	+	485)
	=	0.92

Kyorin Pharmaceutical Co (TSE:4569) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Kyorin Pharmaceutical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyorin Pharmaceutical Co (TSE:4569) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311

Website

https://www.kyorin-pharm.co.jp

Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines